Triple-negative breast cancer (TNBC) cells depend on the transcriptional kinases CDK12 and CDK13 to maintain DNA damage response gene expression and manage replication stress. Due to their functional overlap, inhibition of a single kinase may permit compensatory activity.

Dewpoint Therapeutics Inc. has selected a development candidate in its MYC program. The first-in-class small molecule is designed to disrupt MYC-driven oncogenic transcription by modulating the aberrant biomolecular condensates that organize transcriptional control in cancer cells.

The malfunction of lymphatic drainage that occurs in lymphedema leads to excessive cholesterol accumulation in the affected skin and lymphatic vessels, causing inflammation and fibrosis. However, surgery and the chemical reduction of accumulated cholesterol with cyclodextrin reduce inflammation and regenerate lymphatic vessels. Cholesterol is a potential therapeutic target for treating lymphedema, according to this study published on Feb. 11, 2026, in Nature by Veronique Angeli and her colleagues.

Tempest Therapeutics Inc. has outlined plans to advance its newly acquired CAR T assets. While prioritizing development of its clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 (ERI-2003), the company will also expand its portfolio into next-generation modalities.

Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering.